The Australian biotechnology company CSL and Swiss biotechnology company Alentis Therapeutics are collaborating globally to advance an experimental drug candidate, lixudebart, for rare kidney and liver diseases. In this exclusive CSL and Alentis partnership deal, the companies will co-develop and co-promote lixudebart. CSL will pay Alentis an upfront $355 million and could provide up to $ 1.2 billion in commercial milestone payments. The companies will also share global profits if the treatment reaches the market.
What Does the CSL and Alentis Partnership Deal Include?
The CSL Alentis drug development agreement gives CSL and Alentis shared responsibility for developing and commercialising lixudebart across multiple potential indications.
Under the CSL and Alentis Partnership Deal:
- CSL will make an upfront payment of US$355 million to Alentis.
- Alentis could receive up to US$1.2 billion in commercial milestone payments.
- CSL will fund completion of the ongoing Phase 2 RENAL trial.
- CSL will fund a planned Phase 3 trial in AAV-RPGN.
- CSL will also fund Phase 2 trials in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC).
- If lixudebart is commercialised, CSL will receive 55% of global profits, while Alentis will receive 45%.
The structure makes the CSL Alentis drug development agreement significant, while giving Alentis access to CSL’s global clinical development and commercial capabilities.
What Is Lixudebart?
Alentis lixudebart, formerly known as ALE.F02, is an investigational monoclonal antibody. It selectively targets exposed claudin-1, a protein involved in inflammatory and fibrotic signalling.
Fibrosis refers to the buildup of scar tissue that can progressively damage organs. Lixudebart is designed to produce both anti-inflammatory and anti-fibrotic effects, potentially limiting organ damage in diseases affecting the kidney, liver, lung and other organs.
The drug has also received FDA Orphan Drug designation for idiopathic pulmonary fibrosis, adding to its potential development opportunities.
Which Diseases Does CSL and Alentis Partnership Deal Target?
The CSL kidney disease drug program currently focuses on AAV-associated vasculitis with rapidly progressive glomerulonephritis, or AAV-RPGN.
AAV-RPGN is a rare and potentially life-threatening autoimmune disease in which the immune system attacks small blood vessels in the kidneys. Kidney function can decline rapidly over days or weeks, potentially leading to irreversible damage and end-stage kidney disease.
The CSL and Alentis partnership deal will also expand lixudebart development into:
- Focal segmental glomerulosclerosis (FSGS): A rare progressive kidney disease.
- Primary sclerosing cholangitis (PSC): A chronic autoimmune liver disease.
This multi-indication strategy could allow the CSL and Alentis to investigate one drug across several serious diseases.
What Results Do the Lixudebart Clinical Trials Show?
The lixudebart clinical trial program has produced early signals that support continued development, although the drug remains investigational.
An interim analysis of 26 patients with AAV-RPGN in the Phase 2 RENAL trial showed promising improvements in kidney function at 24 weeks.
Separately, the Phase 1b FEGATO trial enrolled 41 patients with advanced F3/F4 liver fibrosis and showed improved liver function at six weeks. Both studies showed dose-dependent engagement with the claudin-1 target and reported a favourable safety and tolerability profile.
However, these findings are early-stage results. Larger and later-stage clinical trials for lixudebart will need to establish whether lixudebart can deliver meaningful benefits and support regulatory approval.
Why the CSL Alentis Rare Disease Partnership Matters?
The CSL and Alentis partnership deal strengthens CSL’s strategy to build a broader global nephrology business. CSL brings experience in kidney disease development and global commercialisation, while Alentis contributes expertise in claudin-1 biology and its clinical-stage pipeline.
CSL Executive Vice President & Head of R&D, Bill Mezzanotte, said “We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease and helps prevent progression.”
For Alentis, the agreement provides resources and development expertise to accelerate lixudebart across several disease areas. Alentis CEO Mark Pruzanski said, “CSL’s capabilities in AAV and kidney diseases made it the right partner to bring the drug to patients.”
What Happens Next for Lixudebart?
The next stage of the CSL Alentis drug development agreement will focus on completing the ongoing Phase 2 RENAL trial and advancing planned studies in AAV-RPGN, FSGS and PSC.
Future clinical results will determine whether lixudebart can progress toward regulatory submissions and potential commercialisation. For now, the CSL and Alentis partnership deal gives the experimental therapy a broader development pathway while CSL expands its focus on rare kidney and liver diseases.
